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The impact of age on changes in quality of life
among breast cancer survivors treated with
breast-conserving surgery and radiotherapy
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J H Maduro*,1 and E R van den Heuvel2
1Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, PO Box 30 001, 9700 RB
Groningen, The Netherlands; 2Department of Epidemiology, University of Groningen, University Medical Center Groningen, PO
Box 30 001, 9700 RB Groningen, The Netherlands and 3Department of Health Psychology, University of Groningen, University
Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands
Background: The purpose of the study was to determine the impact of young age on health-related quality of life (HRQoL) by
comparing HRQoL of younger and older breast cancer patients, corrected for confounding, and of young patients and a general
Dutch population.
Methods: The population consisted of breast cancer survivors (stage 0-III) after breast-conserving surgery and radiotherapy.
Health-related quality of life was prospectively assessed using the EORTC QLQ-C30 and QLQ-BR23 questionnaires.
The association between age (p50; 51–70; X70 years) and HRQoL over time was analysed with mixed modelling. The clinical
relevance of differences between/within age groups was estimated with Cohen’s D and consensus-based guidelines. The HRQoL
data from the young patient cohort were compared with Dutch reference data at 3 years after radiotherapy.
Results: A total of 1420 patients completed 3200 questionnaires. Median follow-up was 34 (range 6–70) months. Median age was
59 (range 28–85) years. Compared with older subjects, young women reported worse HRQoL in the first year after radiotherapy,
but clinical relevance was limited. Three years after radiotherapy, HRQoL values in the younger group were equal to those in the
reference population. Pain and fatigue after radiotherapy improved, with medium clinical relevance.
Conclusions: Three years after radiotherapy for breast cancer, young age was not a risk factor for decreased HRQoL.
In the Netherlands, breast cancer is the most common malignancy
in women with a yearly incidence of B14 000 cases and is rising
(Netherlands Cancer Registry, 2014a,b). Early-stage breast cancer
is treated with different modalities and may consist of surgery,
radiotherapy and systemic treatment, including chemotherapy,
endocrine treatment and targeted agents. The addition of these
various treatment modalities improved treatment outcome sig-
nificantly in terms of overall survival (Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) et al, 2011), with 5-year survival
rates for stage I–II of 492% (Bantema-Joppe et al, 2013;
Netherlands Cancer Registry, 2014a,b).
Together with increasing breast cancer incidence, this
improved outcome has resulted in a growing population of
cancer survivors. The multimodality strategies may result in
increased treatment-related side effects, ultimately leading to
increased numbers of patients suffering from transient,
persisting or even progressive late side effects (Gartner et al,
2009; Peuckmann et al, 2009; Hill-Kayser et al, 2011).
In addition to the cancer diagnosis itself, these treatment-
related side effects may have a major impact on patients’
health-related quality of life (HRQoL) (Hau et al, 2013; Taghian
et al, 2014).
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In the general non-cancer population, HRQoL depends on a
number of factors, such as co-morbidities, sex, and age (Hjermstad
et al, 1998; Schwarz and Hinz, 2001; Yun et al, 2007), the latter
reflecting the normal process of ageing (Hjermstad et al, 1998). In
cancer survivors, this normal process of ageing may influence
adjustment to cancer and treatment over time. Thus, HRQoL
measurements can be affected by age (Schroevers et al, 2004).
Published data suggest that breast cancer has a greater impact on
HRQoL in younger patients than in older ones (Schroevers et al,
2004; Howard-Anderson et al, 2012; Koch et al, 2013; Champion
et al, 2014; Morrow et al, 2014) and a reduction in impact is seen
with increasing age (Schroevers et al, 2006). However, other studies
have not differentiated between the normal process of ageing and
the impact of age on HRQoL. Therefore, in our study we made a
direct comparison of age-related HRQoL outcome of Dutch breast
cancer patients with reference data from the general Dutch
population (van de Poll-Franse et al, 2011). Since young patients
seem at higher risk for a large decrease in HRQoL after cancer
treatment, we focussed specifically on this patient group.
In our prospective study, disease-free patients had been treated
for early-stage breast cancer with breast-conserving surgery and
radiotherapy were included. Our primary objective was to compare
changes over time in various domains of HRQoL in breast-
conserved breast cancer patients between younger and older
survivors, adjusted for confounding factors. Our secondary
objective was to compare HRQoL in the younger patient cohort
with the general population.
MATERIALS AND METHODS
Study population and data collection. The study population
consisted of consecutive disease-free female patients treated for
breast cancer (stage 0-III) with postoperative radiotherapy after
breast-conserving surgery, from January 2005 to March 2012 at the
department of radiation oncology at the University Medical Center
Groningen. Excluded were patients with a previous history of
invasive cancer, except non-melanoma skin cancer or carcinoma
in situ of the cervix; patients previously treated with radiotherapy
to the thorax; patients diagnosed with synchronous contralateral
breast cancer; patients treated with neo-adjuvant chemotherapy;
patients with prophylactic ipsilateral mastectomy; and patients
with insufficient proficiency in the Dutch language.
Since April 2008, all new breast-conserved patients treated at
our department and all patients previously treated have been
enrolled in a standard follow-up programme (SFP). Patients who
were already in follow-up are seen yearly, and new patients are
generally seen at 6 months after completion of radiotherapy and
thereafter yearly, up to 5 years after radiotherapy.
In the SFP, data on quality of life and toxicity are prospectively
collected, in addition to patient, tumour and treatment-related
data. Furthermore, the National Cancer Institute (NCI) co-
morbidity index for breast cancer patients, modified according to
Klabunde et al (2007), is used to assess co-morbidity. The SFP is
used to monitor outcomes and is conducted under compliance of
the hospital institutional review board regulations.
HRQoL questionnaires. During the routine follow-up visits at our
department, patients were asked to complete the European
Organisation for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire (QLQ)-C30 together with the
EORTC QLQ-BR23 version 3.0 (Aaronson et al, 1993). The
EORTC QLQ-C30 measures several dimensions in functioning and
symptoms as well as global health status. The EORTC QLQ-BR23
focuses on systemic therapy side effects, arm and breast symptoms,
and includes several sexual items.
Reference data (a representative sample of the normal Dutch
population) were obtained from the Health and Health Complaints
project from CentERdata. The EORTC QLQ-C30 and five
additional questions on sexual items were available (van de Poll-
Franse et al, 2011). Two sexual items were identical to the sexual
functioning scale of the QLQ-BR23 module. We used reference
data from young women (p50 years) (N¼ 380).
We focussed on scales that we considered to be specifically
important to young women and on complaints commonly
observed after radiotherapy. We used the following scales in our
analysis: global health status, role functioning, emotional function-
ing, cognitive functioning, sexual functioning (all functional
scales), fatigue, and pain (symptom scales). For functional scales,
higher scores indicate better levels of functioning and/or better
quality of life, while in symptom scales higher scores indicate more
complaints.
Treatment. All patients were treated with post-operative three-
dimensional conformal radiotherapy with a simultaneous inte-
grated photon boost (3D-CRT-SIB). The 3D-CRT-SIB was applied
as described earlier (van der Laan et al, 2007). The fractionation
schemes used were 28 1.8Gy to the whole breast, and with a
simultaneous dose of 2.3 or 2.4Gy to the tumour bed (total dose
64.4 or 67.2 Gy). Regional radiotherapy, if indicated, consisted of
photon radiotherapy of 28 1.8Gy to the regional nodal areas.
Patients with node-positive disease and high-risk node-negative
tumours were treated with adjuvant systemic therapy. Chemother-
apy generally consisted of five cycles of 5-fluorouracil, epirubicine
and cyclophosphamide (FEC) (90% of the patients treated with
chemotherapy). In total, 4.4% of the patients received taxane
chemotherapy. In general, patients with positive lymph nodes were
treated with chemotherapy before radiotherapy. In node-negative
patients, radiotherapy was delivered after primary surgery and
before the chemotherapy. Adjuvant endocrine treatment was
indicated for all intermediate and high-risk hormonal receptor-
positive patients. Depending on menopausal status, tamoxifen or
aromatase inhibitors were given. Trastuzumab was added in
patients receiving chemotherapy with tumours over-expressing the
human epidermal growth factor receptor 2 (HER2).
Statistical analysis. Contingency tables were used to present the
patient characteristics, stratified according to three age categories
(p50 vs 51–70 vsX70 years at start of radiotherapy) with the chi-
square test for comparison.
A generalised linear mixed model was used to determine the
association between age and HRQoL over time, corrected for
potential confounders. Tumour size (42 cm vs p2 cm, based on
the diameter of the primary tumour), pathologic nodal stage
(pNþ vs pN0), axillary clearance (yes vs no), adjuvant systemic
therapy (endocrine treatment vs chemotherapy vs both endocrine
and chemotherapy vs none), adjuvant trastuzumab (yes vs no),
regional radiotherapy (yes vs no), and co-morbidity (medium/high
vs low) were considered. Because of the high correlation (Pearson’s
R40.80) between lymph-node status and axillary clearance, only
axillary clearance was included in the model. The covariates
without significant confounding effect were not included in the
model. With this correction we were able to investigate the
association between age and HRQoL over time independent of the
other factors. A model was estimated for each scale separately. In
the analyses of all end points, except for sexual functioning, the
intercept and slope of follow-up time of patients (defined as time
since completion of radiotherapy (continuous)) were considered to
be random. For sexual functioning, only a random intercept was
considered. Age category and the interaction with follow-up time,
and all potential confounders were considered to be fixed effects.
The interaction of age with follow-up time indicated if the change
in HRQoL over time was different for the three age categories
(p50 years was the reference category) and was tested with the
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likelihood ratio test. Note that this longitudinal data analysis fits
patient-specific time profiles, takes into account the dependence
between repeated observations on the same subject, and has the
advantage of handling repeated data of subjects with varying
numbers and unequally spaced follow-up times (Garson, 2012). In
addition, the proposed models are typically suitable to analyze
non-normally distributed response variables that are discrete and
range from 0 to 100.
The clinical relevance of the differences between young and
older patients and the changes over time was estimated with the
consensus-based guidelines of Cocks et al (2011, 2012) on the
interpretation of EORTC QLQ-C30 scores (trivial, small, medium
or large mean differences per scale) and by calculating Cohen’s D.
Cohen’s D is an effect size used to compare differences between
two means to the standard deviation of the whole population
(Cohen, 1988). Effect sizes of 0.20–0.50 are generally considered
small, 0.50–0.80 are moderate and clinically relevant, and 0.80 and
above are considered a large effect and thus highly relevant. For the
scales not included in the guidelines, changes were classified only
by calculating Cohen’s D. The agreement between the two
classifications was good. The between-persons variation in our
cohort was very large and much larger than the within-persons
variation. Therefore, if available, we preferred to focus on the
Cocks’ classification.
To observe the changes in HRQoL over time, based on ageing in
the reference population, the reference data from young subjects
were analysed with a similar generalised linear model, including
age in years and co-morbidity as covariates. For comparison,
the NCI co-morbidity index was used as calculated in the breast
cancer cohort. To test for mean differences in HRQoL between the
prediction scores of young breast cancer patients and the young
reference population at 3 years after completion of radiotherapy, a
T-test was used. This time point was chosen because it was the
longest follow-up with a reasonable number of questionnaires
available. To address the problem of multiple testing, two-sided
probability values ofo0.010 were considered as statistically
significant.
The statistical software SPSS (SPSS Inc, Chicago, IL, USA) for
Windows, version 20.0, and SAS (Institute Inc, Cary, NC, USA),
version 9.3 was used for statistical analysis.
RESULTS
Patient characteristics. During follow-up, 1548 patients were
asked to complete the HRQoL questionnaires. In total, 1420
patients responded (overall compliance rate: 92%) and 3200
completed questionnaires were available. Not all patients com-
pleted the 5-year follow-up; some had incomplete follow-up period
and others were lost to follow-up. Consequently, different numbers
of questionnaires were available per patient: 401 patients
completed 1 questionnaire, 452 patients completed 2 question-
naires, 336 patients completed 3 questionnaires, and 231 patients
completed 4 questionnaires. All questionnaires were included in
the analysis.
During follow-up, the number of completed questionnaires
decreased and missing data increased. In general, o10% of the
data were missing within the scales. Sexual functioning was an
exception, with missing data ranging from 8% at 1 year to 29% at 5
years of follow-up (Supplementary Material).
Median follow-up time since completion of radiotherapy was 34
(range 6–70) months. At start of radiotherapy, the median age of
all patients was 59 (range 28–85) years, and 292 patients (21%)
were 50 years or younger. Patients’ characteristics, stratified for
age, are summarised in Table 1. Several factors were imbalanced
between the three age groups. Young patients had significantly
larger tumours, more lymph node positivity; consequently, they
underwent axillary clearance more frequently and received
adjuvant systemic therapy and trastuzumab more often. The older
group patients (X70 years) had more co-morbidities, although
74% had generally good health status, with low co-morbidity
scores.
HRQoL functional scales. The crude end point measures with
means and standard errors stratified for age over time are
presented in the Supplementary Material (1. Functional scales
and 2. Symptom scales).
The model of the HRQoL scales included the following
confounders: axillary clearance, adjuvant systemic therapy, regio-
nal radiotherapy, and co-morbidity. By including these confoun-
ders, the predicted HRQoL outcomes of the breast cancer survivors
are adjusted for these variables. The model thus predicts HRQoL in
women treated without axillary clearance, without adjuvant
systemic therapy, without regional radiotherapy, and with few
co-morbidities after radiotherapy. Changes over time therefore
represent only the effect of age. The lines in Figure 1 show the
corrected HRQoL functional outcomes over time of the three age
groups in the breast cancer cohort and the scores of the young
reference population at one time point.
In general, HRQoL functional outcomes were good, with mean
scores fluctuating around 90 points. Immediately after radio-
therapy, the global health status of the three age groups was not
significantly different (Table 2). Over time, the young age group
showed a trend towards better global health, in contrast to the
oldest group, which showed a trend towards worse global health
(P¼ 0.004). However, none of the age groups showed significant or
clinically relevant changes over time. At 3 years of follow-up, the
young breast cancer patients had comparable global health to the
reference population (P¼ 0.012).
Immediately after completion of radiotherapy, the young breast
cancer survivors showed significantly worse HRQoL outcomes
compared with older age groups on all other functional scales,
except for sexual functioning. The outcomes for cognitive and
emotional functioning in young women were worse than both the
middle-aged and older women. With regard to role functioning,
their scores were significantly worse than the middle-aged group
but not the oldest group. However, based on Cohen’s D and Cocks
et al., these differences between the age groups were small or of
trivial clinical relevance.
The development of role, emotional, and cognitive functioning
over time of the oldest age group differed from the two younger age
groups (role functioning Po0.001; emotional functioning
P¼ 0.010, and cognitive functioning Po0.001), with a trend
towards better outcomes in the younger group and worse outcomes
in the oldest age group. On the scores for role and emotional
functioning, this positive trend over time increased significantly
(Po0.001). These improvements over time were of trivial clinical
relevance in the middle-aged group. Although the significant
improvement over time of the scores of the young women on these
three scales was of small clinical relevance, at 3 years after
radiotherapy this group had recovered to the levels in the young
reference population (Figure 1B, role functioning; Figure 1C,
emotional functioning; and Figure 1D, cognitive functioning).
The mean predicted scores of sexual functioning were worse
than the other functional scales, with large and significant
differences between the three age groups directly after radiotherapy
(Po0.001). Based on Cohen’s D, the differences in sexual
functioning between the young and oldest age group were
moderate and clinically relevant. As in the reference population
(data not shown), the mean sexual functioning was best in the
youngest group, followed by the middle aged. Mean sexual
functioning did not change over time in any of the age groups
(P40.010). At 3 years after radiotherapy, the difference in sexual
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functioning between the young breast cancer patients and the
young reference population was not statistically significant
(P¼ 0.044) (Figure 1E, sexual functioning).
The presence of co-morbidities negatively impacted mean
outcomes of all functional scales. Role functioning was significantly
worse in patients who had an axillary clearance (P¼ 0.006) or who
were treated with the combination of chemotherapy and endocrine
therapy compared with no systemic therapy (Po0.001). Both the
combination of chemotherapy and endocrine therapy and
chemotherapy alone were associated with lower mean scores in
cognitive functioning as compared with no systemic therapy
(P¼ 0.001). Additional radiotherapy to the nodal areas was
negatively associated with sexual functioning (P¼ 0.005) (data
not shown).
HRQoL symptom scales. The mean predicted scores of the
symptom scales are shown in Figure 2. In general, patients had few
complaints, with mean scores of 15 points directly after radio-
therapy. The young patients had significantly more fatigue and
pain after radiotherapy, compared with the middle-aged patients
(Po0.001 and P¼ 0.005), with limited clinical relevance. In all
three age groups, a significant improvement over time was
observed for the symptom scales. These improvements were
largest in the youngest age group and of small (Cohen’s D) to
medium (Cocks et al.) clinical relevance, depending on which
classification was used (Table 2). At 3 years after completion of
radiotherapy, no significant differences were observed between the
young patients and the young women from the reference
population (P40.010).
Patients with co-morbidities had significantly more complaints
of fatigue and pain, than those without co-morbidities (Po0.001
and Po0.001). After an axillary clearance, patients reported
significantly more pain (P¼ 0.001).
DISCUSSION
The results of our prospective cohort study indicate that in the first
year after radiotherapy, several domains of HRQoL—such as role
functioning, emotional functioning, cognitive functioning, fatigue,
and pain—are more strongly affected in young breast-conserved
cancer survivors than in older patients. At 3 years after
radiotherapy, the patients appear to recover to the corresponding
HRQoL values of young Dutch women from the general
population. The changes over time on the symptom scales for
pain and fatigue were clinically most relevant. Young patients had
better sexual functioning compared with older patients, but no
significant difference with the reference population.
Overall HRQoL. These findings are supported by previous
studies. In two studies by Schroevers et al (2006, 2004), HRQoL
was most affected in young survivors of several types of
malignancies (50% of the sample had breast cancer). The largest
improvement in HRQoL was observed in the first year after
diagnosis; after 8 years no significant differences in HRQoL were
observed in the survivors of all ages compared with a reference
population.
Table 1. Patient characteristics, stratified according to age (n¼1420)
Characteristic p 50 years, n¼292 51–70 years, n¼895 X70 years, n¼233
Median age (range) in years 46 (28–50) 60 (51–69) 73 (70–85)
n n n P-valuea
Pathologic T-stage o0.001b
pT in situ 6 (2.1%) 31 (3.5%) 7 (3.0)
pT1 177 (60.6%) 667 (74.5%) 175 (75.1)
pTX2 109 (37.3%) 197 (22.0%) 51 (21.9)
Pathologic N-stage o0.001
pN0 182 (62.3%) 633 (70.7%) 188 (80.7)
pNþ 104 (35.6%) 234 (26.1%) 40 (17.2)
pNx 6 (2.1%) 28 (3.1%) 5 (2.1)
Tumour size o0.001
p 2 cm 181 (62.2%) 685 (76.9%) 180 (77.3)
4 2 cm 110 (37.8%) 206 (23.1%) 53 (22.7)
Axillary clearance o0.001
No 180 (61.6%) 637 (71.2%) 190 (81.5)
Yes 112 (38.4%) 258 (28.8%) 43 (18.5)
Adjuvant systemic therapy o0.001
No 80 (27.4%) 401 (44.8%) 130 (55.8)
Endocrine treatment 10 (3.4%) 175 (19.6%) 96 (41.2)
Chemotherapy 51 (17.5%) 100 (11.2%) 5 (2.1)
Endocrineþ chemotherapy 151 (51.7%) 219 (24.5%) 2 (0.9)
Adjuvant trastuzumab 0.001
No 268 (91.8%) 843 (94.2%) 231 (99.1)
Yes 24 (8.2%) 52 (5.8%) 2 (0.9)
Regional radiotherapy 0.16
No 269 (92.1%) 835 (93.3%) 224 (96.1)
Yes 23 (7.9%) 60 (6.7%) 9 (3.9)
Co-morbidity o0.001
Low 273 (93.5%) 769 (85.9%) 173 (74.2)
Medium/high 19 (6.5%) 126 (14.1%) 60 (25.8)
aCalculated with chi-square statistics.
bBold values signify P-values ofo0.01.
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A systematic review on HRQoL and menopause-related
symptoms in young breast cancer survivors showed that overall
quality of life was compromised; mental functioning domains of
HRQoL were affected more severely than physical functioning
(Howard-Anderson et al, 2012). In our study, both the physical
and the mental domains were impacted more in the youngest
patient group immediately after completion of radiotherapy
compared with older patients. However, our analysis showed that
this finding has small clinical relevance.
Despite this worse HRQoL in young women immediately after
radiotherapy, the improvements over time were also largest in this
age group. On most functional scales, the changes were considered
to be of small clinical relevance and in the symptom scales of
medium relevance. Recently, Hsu et al (2013) observed improve-
ments over time in many domains of HRQoL, assessed in long-
term breast cancer survivors, with a relatively low mean age of 49.8
years at diagnosis, at both 1-year and 12-year post diagnosis. At 12
years after diagnosis, no clinically important differences were
observed between breast cancer survivors and age-matched women
without history of breast cancer in overall quality of life, role
functioning, emotional functioning, and fatigue. The breast cancer
patients reported even less pain than controls.
In several other studies on HRQoL in breast cancer patients,
young age was a risk factor for poorer HRQoL and distress after
treatment (Ganz et al, 2003; Engel et al, 2004; Hopwood et al, 2007;
Hartl et al, 2010; Luutonen et al, 2011; Hau et al, 2013; Morrow
et al, 2014). In our study, however, we found no differences in
HRQoL between young breast cancer patients at 3 years after
radiotherapy and an age-matched Dutch reference population.
This difference in results is probably because we determined the
independent effect of age by correcting for all other potential risk
factors for decreased HRQoL, such as the administration of
chemotherapy and endocrine treatment. The other studies did not
make this correction.
The observed improvements over time in overall HRQoL,
especially for young women, are probably the result of several
mechanisms. First, a true improvement over time, with fewer
physical complaints, may be present after the initial stress of
diagnosis and first treatment phase. In young women, the observed
recovery is larger than in older women. Young women have more
physical flexibility and larger capacity to recover. In older women
this capacity to recover is smaller, and is also influenced by the
process of ageing itself. Second, and probably interacting with the
first mechanism, the HRQoL measurements may be influenced by
response shift. This means that the basis on which people make an
HRQoL self-evaluation may also shift over time. However, the
clinical significance of response shift is still unclear (Schwartz et al,
2006). One example of response shift can be observed our data on
global health status, a scale on general quality of life. On this scale,
young breast cancer survivors had at least comparable, and
borderline significantly better HRQoL, compared with the
reference population at 3 years of follow-up.
P = 0.200
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P = 0.488
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5 0 1 2 3 4 5
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Figure 1. Predicted health-related quality of life of the functional scales of breast cancer survivors, compared with outcomes of a young Dutch
reference population, stratified for age. Higher scores indicate better health-related quality of life. The lines represent outcomes in women
treated without axillary clearance, without adjuvant systemic therapy, without regional radiotherapy, and with few co-morbidities present:
(A) global health status, (B) role functioning, (C) emotional functioning, (D) cognitive functioning, and (E) sexual functioning. The outcomes
of the young survivors are compared with the reference population at 3 years after completion of radiotherapy (P-value).
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Pain and fatigue. On the symptom scales, fatigue and pain, which
are commonly reported after radiotherapy, we observed a significant
improvement over time in all age groups. Goldstein et al (2012)
investigated cancer-related fatigue in 218 patients and concluded
that fatigue after breast cancer is common, but generally self-
limiting. In our larger cohort we confirmed this finding, which is
opposite to what is generally perceived. Furthermore, based on
multivariate analysis in an earlier study, Goldstein et al (2012) found
that age was not a risk factor for fatigue after more than 6 months
following adjuvant treatment. In contrast, we observed differences in
fatigue between young and older patients after radiotherapy.
In previous research in 532 women treated with radiotherapy
after breast-conserving surgery, we reported a higher incidence of
pain in the chest wall in young patients at 1 year after radiotherapy
(p50 years of age at diagnosis) compared with older women
(Bantema-Joppe et al, 2012). This could be explained by the
misattribution of pain and the decreased tendency to label a
sensation as painful with increasing age (Gartner et al, 2009).
Visser et al (2013) showed that response shift has a small, but
unique contribution to the explanation of bodily pain after invasive
surgery in cancer patients. Besides response shift, a true reduction
in physical complaints may also be responsible for the observed
improvements in pain over time.
Sexual functioning. Immediately after radiotherapy, sexual func-
tioning differed significantly between the three age groups, with
Table 2. Predicted outcomes of the HRQoL scales, immediately after completion of RT and 3 years after completion of
radiotherapy and the clinical relevance of the differences observed, stratified according to agea
Directly after RT
HRQoL scales
Global health status no no no no
Role functioning no S S S
Emotional functioning - S S S
Cognitive functioning S S S S
Sexual functioning - no - M
Fatigue S S S no
Pain S S S S










Global health status no no no
Role functioning S no no
Emotional functioning S no no
Cognitive functioning S no S
Sexual functioning - - -
Fatigue M S no
Pain M S no
CRc Cohen’s D
Global health status no no no
Role functioning S no no
Emotional functioning S no no
Cognitive functioning S no no
Sexual functioning no no no
Fatigue S no no
Pain S S no






















Ref pop Breast cancer pop
≤50 50-70 ≥70
80.4 87.7 89.9 85.1
Mean Mean Mean Mean
86.9 89.9 93.4 91.9
93.0 97.3 97.6 93.6
41.7 29.5 20.5 5.8
94.4 94.4 96.2 94.1
10.6 5.5 3.6 5.1
16.9 11.2 7.7 12.5
Effect size over time within groups
ref vs. breast









Abbreviations: CR¼ clinical relevance; HRQoL¼health related quality of life; RT¼ radiotherapy—¼ not available.
aPredicted scores for the specific subgroup of patients, treated with no axillary clearance, without adjuvant systemic therapy, without regional radiotherapy or co-morbidity.
bCR classification of the clinical relevance based on Cocks: ‘no’¼ ‘trivial’; ‘S’¼ ‘small’ (light grey); ‘M’¼ ‘medium’ (dark grey) differences.
cCR classification of the clinical relevance based on Cohen’s D: ‘no’¼ ‘no clinical relevance’; ‘S’¼ ‘small’ (light grey); ‘M’¼ ‘moderate’ (dark grey) effect.
dP-value of the comparison between the young breast cancer group and young reference population at 3 years after completion of radiotherapy.
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best sexual functioning in the youngest group and the worst in the
oldest group. In contrast to nearly all other HRQoL domains, no
changes over time in any age group were observed. The lack of
change over time cannot be explained by the use of systemic
treatment, resulting in vaginal dryness (Varras et al, 2003; Cella
and Fallowfield, 2008) since we controlled for systemic treatment.
The borderline insignificant difference in sexual functioning
between the young breast cancer patients and the young Dutch
women at 3 years might be attributed to the large amount of
missing data. The relatively large proportion of missing data in the
sexual functioning domain could have resulted in a lack of power
to show differences. More specific research is needed on the effects
of breast cancer treatment on sexual functioning.
Limitations. No data on socio-demographics and psychosocial
factors were available for the breast cancer population. Health-
related quality of life outcomes could have been influenced by these
factors, thus limiting the generalisability of comparisons between
the age groups of breast cancer patients and between the young
breast cancer patients and the reference population.
Another limitation of our study was the number of missing
questionnaires. In the statistical analysis, we assumed that the
missing data were missing at random. Investigating the possible
reasons for having missing data by Generalised Estimating
Equations did not indicate otherwise. However, by including all
patients, irrespective the number of questionnaires available, we
could have biased the outcomes. First, patients without any health
complaints were probably less likely to attend out-patient visits,
leading to an underestimation of HRQoL. Second, patients with very
serious non-cancer health problems might miss one or the rest of the
follow-up visits, leading to an overestimation of the quality of life.
Longitudinal data in the reference population were also lacking.
By matching the mean age and range of the reference group with
the young breast cancer survivors at completion of radiotherapy,
we were able to predict the HRQoL outcomes at that point in time.
Age was then corrected by adding the follow-up time. By these
means, we could compare and test for differences between the
HRQoL of the young breast cancer cohort and the reference
population, the latter reflecting normal ageing.
CONCLUSION
In our large prospective study, young women treated with
radiotherapy after breast-conserving surgery for breast cancer
have worse HRQoL in the first year after radiotherapy compared
with their older counterparts, with small but significant clinical
relevance. However, at 3 years after radiotherapy, they appear to
recover to the values of the normal young Dutch population. These
results indicate that on the medium long-term young age is not an
independent risk factor for decreased HRQoL after radiotherapy in
breast-conserved cancer patients.
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